Evidence map›Paper›PMID 40472897›Full record

Observational studyOphthalmology. Glaucoma

Short-Term Rates of Visual Field Change Predict Glaucoma Progression.

Mohsen Adelpour, Sasan Moghimi, Takashi Nishida, Leo Meller, Kelvin H Du, Alireza Kamalipour, Natchada Tansuebchueasai, Golnoush Mahmoudinezhad, Linda M Zangwill, Robert N Weinreb

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohsen AdelpourViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Sasan MoghimiViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Takashi NishidaViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Leo MellerViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Kelvin H DuViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Alireza KamalipourViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Natchada TansuebchueasaiViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California; Faculty of Medicine, Department of Ophthalmology, Prince of Songkla University, Songkhla, Thailand.
Golnoush MahmoudinezhadViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Linda M ZangwillViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California.
Robert N WeinrebViterbi Family Department of Ophthalmology, Shiley Eye Institute, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California. Electronic address: rweinreb@ucsd.edu.

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography AngiographyR01EY029058 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINREB, ROBERT N · 2018 to 2024
$4.2M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
Monitoring of Glaucoma Patients in Advanced DiseaseR01EY034148 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sasan Moghimi Araghi · 2022 to 2026
$2.5M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS R01 EY029058NEI NIH HHS R01 EY034148
6 · The paper itself

Abstract

purposeTo explore the prognostic significance of short-term rates of visual field (VF) mean deviation (MD) change in predicting progression across various levels of glaucoma severity.

designObservational cohort.

participantsA total of 349 eyes from 254 patients followed up to 5 years.

methodsPrimary open-angle glaucoma eyes were included with ≥ 5 24-2 VFs tests during the initial 2 years over a period of up to 5 years. Two assessment methods, Guided Progression Analysis (GPA) and a United States Food and Drug Administration (FDA)-consistent end point, were utilized to identify progression events. Rates of change in VF MD during the initial 2 years were calculated, and survival models were employed to evaluate the risk of faster initial VF MD loss on the development of GPA and FDA-consistent end points.

main outcome measuresRisk of progression based on initial MD change rates.

resultsOver a mean follow-up of 4.3 years, progression was observed in 17.2% (GPA end point) and 24.9% (FDA-consistent end point) of eyes. Faster initial rates of VF MD loss significantly increased the progression risk (hazard ratio [HR] per 0.1 dB/year faster for GPA: 1.16, 95% confidence interval [CI]: 1.12-1.20; HR for FDA: 1.16, 95% confidence interval: 1.12-1.21; both P < 0.001) with survival-adjusted R

conclusionsThe initial 2-year rate of VF MD change predicts subsequent progression events based on FDA-consistent criteria in both early and moderate-to-advanced glaucoma eyes. These findings suggest initial VF MD change rates identify patients at higher risk of future progression, enabling timely management decisions and, also, potentially serving as a progression end point in clinical trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Glaucoma, Open-AngleIntraocular PressureVisual FieldsAgedDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesTime FactorsVisual Field TestsGlaucomaGlaucoma progressionVisual field

Identifiers

PMID40472897
PMCPMC13529304

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.